By adding a cell-penetrating sequence to the antimicrobial core of bovine lactoferricin, researchers created a peptide (MPLfcinB6) that selectively kills T-leukemia and B-lymphoma cells through irreparable membrane damage.
Selective for blood cancersMPLfcinB6 selectively killed T-leukemia and B-lymphoma cells through irreparable membrane damage — a mechanism fundamentally different from conventional chemotherapy that cancer cells may not easily resist.
What the researchers found
The six-amino-acid antimicrobial core of lactoferricin (LfcinB6, RRWQWR) was not cytotoxic to cancer cells on its own. Adding a hepta-arginine cell-penetrating sequence via a glycine-glycine linker created MPLfcinB6, which was selectively cytotoxic to human T-leukemia and B-lymphoma cells.
The killing mechanism involved extensive and irreparable cell membrane damage, confirmed by propidium iodide uptake, dextran uptake, and scanning electron microscopy. While the peptide also triggered ROS production and mitochondrial membrane permeabilization, neither ROS nor caspase activation was essential for cell death — membrane destruction was the primary killing mechanism.
Why it matters
Blood cancers like leukemia and lymphoma need new treatment approaches, especially for drug-resistant cases. This peptide kills cancer cells through membrane destruction — a mechanism that's very different from conventional chemotherapy and difficult for cancer cells to develop resistance against. The selectivity for blood cancer cells over normal cells addresses a key challenge in anticancer drug development.
How the study worked
Researchers synthesized MPLfcinB6 by conjugating the lactoferricin antimicrobial core (RRWQWR) to a cell-penetrating hepta-arginine sequence via a glycine-glycine linker. Cytotoxicity was assessed against human T-leukemia and B-lymphoma cell lines. Membrane damage was characterized by flow cytometry (propidium iodide and FITC-dextran uptake) and scanning electron microscopy. ROS production, mitochondrial membrane potential, and caspase activation were measured to elucidate the cell death mechanism.
What this study cannot tell us
This is an in vitro study using cancer cell lines — no animal testing or comparison with primary patient cancer cells was performed. Only two types of blood cancer were tested; selectivity against other cancer types and normal blood cells was not comprehensively characterized. The peptide's stability in blood and potential immunogenicity were not assessed. Whether MPLfcinB6 can reach cancer cells in vivo through systemic administration is unknown.
How to read the evidence
This is an in vitro mechanistic study using cancer cell lines. While it clearly demonstrates selective cytotoxicity and elucidates the killing mechanism, all findings are from cell culture without in vivo validation.
When this study was published
Published in 2013, this study contributed to the growing field of anticancer peptides. The concept of engineering selective membranolytic peptides from natural antimicrobial sequences continues to be actively pursued.
The bigger picture
Antimicrobial peptides are increasingly recognized as potential anticancer agents because cancer cell membranes often have different properties (more negatively charged) than normal cells, providing a basis for selectivity. This study demonstrates that minimal peptide sequences can be engineered for selective cancer killing, contributing to the broader field of peptide-based cancer therapeutics that work through membrane disruption — a mechanism largely unexploited by current drugs.
Questions still open
- Is MPLfcinB6 effective against drug-resistant leukemia and lymphoma cell lines?
- What gives cancer cell membranes the properties that make them susceptible to MPLfcinB6 while normal cells are spared?
- Could MPLfcinB6 be effective against solid tumors or is it specific to blood cancers?
Common questions
How does a milk-derived peptide kill cancer cells?
Why is membrane destruction an interesting way to kill cancer?
Read the original research
Generation of a hematologic malignancy-selective membranolytic peptide from the antimicrobial core (RRWQWR) of bovine lactoferricin.
Experimental and molecular pathology, 95(2), 192-8
Citation
Hilchie, Ashley L; Vale, Rachel; Zemlak, Tyler S; Hoskin, David W. (2013). Generation of a hematologic malignancy-selective membranolytic peptide from the antimicrobial core (RRWQWR) of bovine lactoferricin.. Experimental and molecular pathology, 95(2), 192-8. https://doi.org/10.1016/j.yexmp.2013.07.006